Omalizumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solar Urticaria
Conditions
Solar Urticaria
Trial Timeline
Sep 30, 2014 → Sep 29, 2015
NCT ID
NCT02262130About Omalizumab
Omalizumab is a phase 2 stage product being developed by Novartis for Solar Urticaria. The current trial status is completed. This product is registered under clinical trial identifier NCT02262130. Target conditions include Solar Urticaria.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05424523 | Pre-clinical | Completed |
| NCT05157087 | Pre-clinical | Completed |
| NCT04037176 | Approved | Completed |
| NCT02550106 | Approved | Completed |
| NCT02329223 | Phase 3 | Completed |
| NCT02262130 | Phase 2 | Completed |
| NCT02118987 | Phase 1 | Completed |
| NCT02023151 | Approved | Completed |
| NCT01328886 | Phase 3 | Completed |
| NCT01155700 | Phase 3 | Completed |
| NCT00500539 | Phase 3 | Completed |
| NCT00264849 | Approved | Completed |
| NCT00180011 | Phase 2/3 | Completed |
| NCT00639691 | Approved | Completed |
| NCT00226200 | Pre-clinical | Terminated |
| NCT00482248 | Phase 3 | Completed |
| NCT00482508 | Phase 3 | Completed |
| NCT00046748 | Phase 3 | Completed |
Competing Products
1 competing product in Solar Urticaria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| afamelanotide | Clinuvel Pharmaceuticals | Phase 2 | 44 |